InMed Pharmaceuticals Inc (INM)

[Aladdin80]

And I wouldn't necessarily agree. They were working to finalize a priority pathway (path 1) w/a different CDMO partner and hit a brick wall. Couldn't identify a viable work around to remain on path 1 and then began exploring other pathways (partners, process steps, etc) to keep biosynthesis going. This is also where the core of their IP filings as well as transfer of technology resided. Today it sounds like they've had to abandon that path for an alternative or multiple alternatives which is not clear.

Who's to say they don't hit the same wall w/Almac? For me, real progress at this stage is a confirmed path, known costs to produce, scale up and commercialization. Anything else is simply more evaluation, more expenditures and most importantly more delays.